by Alison Bass | Apr 12, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, FDA, health care costs, patient care, pharmaceutical industry, scientific misconduct
I’ve been reading Dr. David Healy’s new book, Pharmageddon, and while some of it may seem like old news, I was struck by his fresh analysis of how the pharmaceutical industry has turned the original purpose of clinical trials inside out. As Healy, a noted...
by Alison Bass | Feb 7, 2012 | antidepressants, clinical trials, conflicts of interest, FDA, ghostwriting, pharmaceutical industry, scientific journal retractions, scientific misconduct
I was hesitant to weigh in at first when I learned that Brown University’s School of Medicine had decided not to pressure a psychiatric journal to retract the seriously flawed Paxil study that I wrote about in Side Effects. After all, Brown has been covering up...
by Alison Bass | Dec 2, 2011 | antidepressants, antipsychotic drugs, clinical trials, conflicts of interest, drug marketing, FDA, ghostwriting, pharmaceutical industry
A new report from the U.S. Government Accountability office confirms something that Rose Firestein, the eponymous prosecutor in the title of Side Effects: A Prosecutor, a Whistleblower and Bestselling Antidepressant on Trial noticed way back in the ’90s: that...
by Alison Bass | Oct 28, 2011 | antidepressants, conflicts of interest, FDA, medical devices, suicide rates
With the Obama administration hobbled by a Republican-led Congress, the pharmaceutical and medical device industry seems to have launched a concerted push to roll back regulatory initiatives designed to protect consumers from unproven or unsafe drugs and medical...
by Alison Bass | Sep 8, 2011 | conflicts of interest, FDA, health insurers, National Institutes of Health, university industry collaboration
At a time when our own government has stepped back from requiring true transparency about conflicts of interest in medicine, French lawmakers seem to be heading in a much bolder direction. According to Nature Medicine, the French national assembly is considering a...
